Wall Street brokerages predict that Davita Inc (NYSE:DVA) will announce earnings of $0.89 per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Davita’s earnings. The lowest EPS estimate is $0.77 and the highest is $0.96. Davita posted earnings per share of $0.92 during the same quarter last year, which indicates a negative year-over-year growth rate of 3.3%. The business is scheduled to announce its next earnings report on Tuesday, February 12th.
On average, analysts expect that Davita will report full-year earnings of $3.56 per share for the current fiscal year, with EPS estimates ranging from $3.45 to $3.63. For the next fiscal year, analysts forecast that the business will post earnings of $4.81 per share, with EPS estimates ranging from $4.36 to $5.03. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Davita.
Davita (NYSE:DVA) last released its earnings results on Wednesday, November 7th. The company reported $0.56 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.89 by ($0.33). Davita had a net margin of 5.39% and a return on equity of 13.87%. The company had revenue of $2.85 billion for the quarter, compared to the consensus estimate of $2.93 billion. During the same period in the prior year, the company earned $0.81 earnings per share. The firm’s revenue was up 3.0% on a year-over-year basis.
A number of research firms have recently weighed in on DVA. Zacks Investment Research downgraded shares of Davita from a “buy” rating to a “hold” rating in a research report on Tuesday, October 23rd. Raymond James raised shares of Davita from a “market perform” rating to an “outperform” rating and set a $70.00 target price for the company in a research report on Wednesday, November 28th. They noted that the move was a valuation call. ValuEngine downgraded shares of Davita from a “buy” rating to a “hold” rating in a research report on Wednesday, October 17th. JPMorgan Chase & Co. raised shares of Davita from an “underweight” rating to a “neutral” rating in a research report on Thursday, September 13th. Finally, TheStreet downgraded shares of Davita from a “b-” rating to a “c+” rating in a research report on Thursday, November 8th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $80.16.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in DVA. Honkamp Krueger Financial Services Inc. bought a new position in Davita in the 3rd quarter worth approximately $143,000. Atlas Capital Advisors LLC boosted its holdings in Davita by 247.9% in the 3rd quarter. Atlas Capital Advisors LLC now owns 2,592 shares of the company’s stock worth $188,000 after buying an additional 1,847 shares during the period. Green Square Capital LLC bought a new position in Davita in the 2nd quarter worth approximately $208,000. IFG Advisory LLC bought a new position in Davita in the 2nd quarter worth approximately $213,000. Finally, Captrust Financial Advisors boosted its holdings in Davita by 96.8% in the 3rd quarter. Captrust Financial Advisors now owns 3,050 shares of the company’s stock worth $218,000 after buying an additional 1,500 shares during the period. 85.76% of the stock is owned by institutional investors.
Shares of Davita stock traded down $3.53 on Thursday, reaching $60.54. 117,541 shares of the company traded hands, compared to its average volume of 2,068,674. Davita has a 52 week low of $58.68 and a 52 week high of $80.71. The company has a market capitalization of $10.64 billion, a P/E ratio of 18.22, a P/E/G ratio of 0.85 and a beta of 1.07. The company has a quick ratio of 1.82, a current ratio of 1.84 and a debt-to-equity ratio of 2.09.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
See Also: What is a Market Correction?
Get a free copy of the Zacks research report on Davita (DVA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.